Ash Stevens gets FDA nod for ixazomib production; Anderson appointed CMO at Symbiosis; Idera inks deal with GSK;

> The FDA has given Ash Stevens ($ASI) the go ahead to begin manufacturing the API ixazomib, an oral proteasome inhibitor used to treat multiple myeloma, at the company's Riverview, MI, facility. Story

> Symbiosis Pharmaceutical Services has appointed Joanne Anderson at its new business development director. Release

> Idera Pharmaceuticals ($IDRA) has entered into a $100 million collaboration and license agreement with GlaxoSmithKline ($GSK) to research, develop and commercialize for the treatment of renal disease. Story

Suggested Articles

The cleaning procedures are so poor at a Zydus Cadila plant in India that the FDA says a sampling found 10 different cross-contaminated products.

Mylan is the most recent drugmaker facing the FDA's ire over a tainted API that led to a global recall of "sartan"-based drugs last year.

Merck MSD's $1.2 billion production restructuring has fallen on a site in France, where more than 200 manufacturing and R&D jobs will be swept away.